Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Cymabay Therapeutics (CBAY)
Cymabay Therapeutics (CBAY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,697,554
  • Shares Outstanding, K 114,724
  • Annual Sales, $ 31,073 K
  • Annual Income, $ -106,000 K
  • 60-Month Beta 0.32
  • Price/Sales 118.85
  • Price/Cash Flow N/A
  • Price/Book 12.49
Trade CBAY with:

Options Overview Details

View History
  • Implied Volatility 25.33% ( -1.09%)
  • Historical Volatility 69.21%
  • IV Percentile 5%
  • IV Rank 9.67%
  • IV High 212.86% on 09/05/23
  • IV Low 5.26% on 02/28/24
  • Put/Call Vol Ratio 0.21
  • Today's Volume 128
  • Volume Avg (30-Day) 1,748
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 38,200
  • Open Int (30-Day) 37,600

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.31
  • Number of Estimates 5
  • High Estimate -0.23
  • Low Estimate -0.35
  • Prior Year -0.29
  • Growth Rate Est. (year over year) -6.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.24 +38.68%
on 02/06/24
32.35 -0.37%
on 03/01/24
+7.84 (+32.14%)
since 02/01/24
3-Month
19.44 +65.79%
on 12/04/23
32.35 -0.37%
on 03/01/24
+12.52 (+63.52%)
since 12/01/23
52-Week
7.26 +343.88%
on 06/27/23
32.35 -0.37%
on 03/01/24
+24.05 (+294.01%)
since 03/01/23

Most Recent Stories

More News
Trimble, CymaBay Therapy rise; Big Lots, Monday.com fall, Monday, 2/12/2024

Stocks that traded heavily or had substantial price changes on Monday: Trimble, CymaBay Therapy rise; Big Lots, Monday

BIG : 5.44 (+0.37%)
TRMB : 62.35 (+1.90%)
BBGI : 0.8615 (-1.09%)
FANG : 185.17 (+1.45%)
CBAY : 32.23 (+0.12%)
Why CymaBay Therapeutics Stock Rocketed Nearly 8% Higher Today

It became increasingly likely that seladelpar will ultimately gain regulatory approval.

CBAY : 32.23 (+0.12%)
Why CymaBay Therapeutics Stock Is Sinking This Week

The stock has given up some of its gains but remains up more than 130% year to date.

CBAY : 32.23 (+0.12%)
Why CymaBay Therapeutics Stock Triumphed Again on Tuesday

The company is about to reap more money than previously expected from a new capital-raising effort.

CBAY : 32.23 (+0.12%)
Why CymaBay Therapeutics Stock Popped Again Today

Days after it reported highly encouraging news from a clinical trial, the company announced a new round of capital-raising.

CBAY : 32.23 (+0.12%)
Why CymaBay Therapeutics Stock Is Jumping Today

The momentum continues after CymaBay reported great clinical results on Thursday.

ICPT : 19.00 (+0.21%)
CBAY : 32.23 (+0.12%)
CymaBay Initiates IDEAL, a Phase 3 Placebo-Controlled, Randomized Study of Seladelpar in Patients with Primary Biliary Cholangitis and Incomplete Control of Alkaline Phosphatase

/PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for...

CBAY : 32.23 (+0.12%)
Why Shares of CymaBay Therapeutics Are Soaring Friday

A competitor's drug had a so-so phase 3 trial, lifting the possibilities for CymaBay's lead therapy.

RJF : 120.07 (-0.21%)
CBAY : 32.23 (+0.12%)
CymaBay Therapeutics Presents Data Showing Seladelpar Treatment in Primary Biliary Cholangitis (PBC) Correlates with Alleviation of Self-Reported Pruritus and Reduction in Serum IL-31 Levels

/PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other...

CBAY : 32.23 (+0.12%)
CymaBay Therapeutics to Present New Data Highlighting Seladelpar's Unique Activity in Patients with Primary Biliary Cholangitis at The International Liver Congress™ 2023

/PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other...

CBAY : 32.23 (+0.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based...

See More

Key Turning Points

3rd Resistance Point 32.48
2nd Resistance Point 32.42
1st Resistance Point 32.32
Last Price 32.23
1st Support Level 32.16
2nd Support Level 32.10
3rd Support Level 32.00

See More

52-Week High 32.35
Last Price 32.23
Fibonacci 61.8% 22.77
Fibonacci 50% 19.81
Fibonacci 38.2% 16.84
52-Week Low 7.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar